EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque-Pereira iD, Christine Leopold, Patrick C Souverein iD, Aukje K Mantel-Teeuwisse, Marie L De Bruin iD

British Journal of Clinical Pharmacology · 2026-04-29

DOI: 10.1002/bcp.70580 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, published online on 2026-04-29. Written by Comfort Kunak Ogar and 6 co-authors. Institution: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlan…. Cited 1 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.

Methods

We descriptively analysed AEFIs to nOPV2 and other vaccines reported to VigiBase from January 1, 2010 to December 31, 2023. Proportional Reporting ratios (PRRs) at Medical Dictionary for Regulatory Activities (MedDRA) higher level group term (HLGT) compared signals of disproportionate reporting (SDR) between nOPV2 and two comparators.

Results

In total, 409 001 AEFIs were included (nOPV2 specific AEFIs: n = 18 911 [4.6%]), of which 54.0% males (n = 10 209) and 22.6% serious (n = 4283). Most events had resolved (n = 9418, 49.8%) or were resolving (n = 6239, 33.0%) at reporting. Body temperature conditions, gastrointestinal and respiratory tract‐related events were most reported to nOPV2. Five ‘novel’, mostly non‐serious SDRs were identified ‐ oral soft tissue conditions (PRR: 2.47, 95% CI: 1.71–3.59), haemoglobinopathies (PRR: 31.53, 95% CI: 3.38–312.72), malabsorption conditions (PRR: 4.65, 95% CI: 1.79–12.09), neoplasm‐related morbidities (PRR: 3.61, 95% CI: 1.44–9.11) and skin and subcutaneous tissue infections and infestations NEC (PRR: 3.55, 95% CI: 2.61–4.82). Among the serious events, nervous system‐related events were reported more. Conclusion nOPV2 appears to retain a positive safety profile in real‐world use. We support its continued use for cVDPV outbreak response and advocate continued monitoring as coverage increases and reporting is no longer mandated.

Subjects

Author keywords

VigiBaseadverse events following immunization (AEFI)novel oral polio vaccine type 2 (nOPV2)safety analysissignals of disproportionate reporting

Authors and institutions

  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • Department of Global Health and Manufacturing Services, United States Pharmacopeia (USP), Rockville, Maryland, USA.
  • Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID profiles: Leonardo Roque-Pereira, Patrick C Souverein, Marie L De Bruin

Cite

APA

Ogar, C. K., Sisay, M. M., Roque-Pereira, L., Leopold, C., Souverein, P. C., Mantel-Teeuwisse, A. K., & De Bruin, M. L. (2026). Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70580

Vancouver

Ogar CK, Sisay MM, Roque-Pereira L, Leopold C, Souverein PC, Mantel-Teeuwisse AK, et al. Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70580

BibTeX
@article{Ogar2026,
  author = {Ogar, Comfort Kunak and Sisay, Malede Mequanent and Roque-Pereira, Leonardo and Leopold, Christine and Souverein, Patrick C and Mantel-Teeuwisse, Aukje K and De Bruin, Marie L},
  title = {Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70580}
}
Start for free →